Develco Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South africaSwitzerland generalMiami beachBaden wübergUnited statesDevelco pharmaHans erikssonKetabon gmbhAnne donohoeAmerican society of clinical psychopharmacologyKetabon programBrain healthDepression at american societyHolding gmbClinical psychopharmacologyAnnual meeting

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Baden wübergCzech republicUnited statesSouth africaSwitzerland generalHans erikssonMckenna millerSophia bashfordDevelco pharmaKetabon gmbhHome administrationBrain healthKetabon programHolding gmbProlonged release oral ketamine formulationFinds less incidence

Study Indicates Take-at-Home, Oral Ketamine is an Effective Option for Treatment-Resistant Depression

The daily oral formulation of ketamine, KET01, has the potential to greatly improve the standard treatment practices for treatment-resistant depression, according to investigators.

Czech republicDevelco pharmaHans erikssonMartin walterPsychotherapy of university jenaDepartment of psychiatryBrain healthUniversity jenaClinician administered dissociative states scaleTop line results from phaseOral ketamine optionKetamine demonstratedBlind trial shows low cost subcutaneous versionEffective over placeboTreating treatment resistant

Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression

Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Czech republicSwitzerland generalBaden wübergSouth africaAnne donohoeSophia bashfordHans erikssonMartin walterDevelco pharmaHolding gmbBrain healthKetabon programUniversity jenaHead of the department psychiatryGmbh reports top line resultsOral ketamine option

Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Investegate announcements from HMNC Holding GmbH, HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression

Baden wübergSwitzerland generalSouth africaAnne donohoeSophia bashfordHans erikssonDevelco pharmaKetabon programBrain healthHolding gmbHmnc brain healthOral prolonged release ketamineTopline results expectedTreatment resistant depressionChief medical officerDepression rating scale